Biopharmaceutical industry analysis can be written that the biopharmaceutical industry has the characteristics of high technology, high investment, long cycle, high risk, high return, and low pollution. Bioengineered drugs have a high return on profit.
A new biopharmaceutical can generally recover all investment 2-3 years after it is launched. Especially for companies with new products and patented products, once developed successfully, they will form a technological monopoly advantage, and the profit return can be as high as More than 10 times.
Biomedicine Trends
High risk means that the development of biomedicine products breeds greater uncertain risks. Investment in new drugs involves biological screening, pharmacology, toxicology and other preclinical experiments, A series of steps from preparation formulation and stability testing, bioavailability testing to clinical trials on humans, as well as registration and marketing and after-sales supervision, can be described as a costly systematic project.
If any link fails, all previous efforts will be wasted, and some drugs have "dual nature" and may have adverse reactions during use and need to be re-evaluated. Generally speaking, the success rate of a bioengineered drug is only 5-10. But it takes 8-10 years and an investment of US$100-300 million.
In addition, the risk of market competition is also increasing day by day. "Seizing new drug certificates and seizing market share" is the key to transforming development technology into products. It is also the goal of fierce competition among different developers. Giving priority to obtaining drug licenses or seizing the market will also be in vain.